Advancing personalized cancer therapy through molecular profiling and the investigation of mechanisms that drive therapy response and treatment resistance.
Precision oncology aims to tailor cancer treatment to the individual biological characteristics of each patient’s tumor. Molecular diagnostics enable the identification of genetic and molecular alterations that influence tumor behavior, prognosis, and treatment response. These analyses provide the basis for individualized therapeutic strategies.
At UCCSH, researchers integrate genomic, transcriptomic, proteomic, and clinical data to better understand tumor biology and guide treatment decisions. Molecular tumor boards bring together experts from multiple disciplines to evaluate molecular diagnostic results and identify potential targeted treatment options for patients with advanced or therapy-resistant cancers.
Despite the promise of personalized therapy, many tumors eventually develop resistance to treatment. Understanding the molecular mechanisms underlying therapy resistance is therefore a major research focus. Studies at UCCSH investigate factors such as genomic instability, tumor heterogeneity, and adaptive cellular responses that enable cancer cells to evade targeted therapies. These insights support the development of new strategies to overcome resistance and improve long-term treatment outcomes.